Skip to main content
Clinical Trials/2024-517831-28-00
2024-517831-28-00
Not yet recruiting
Phase 4

Monitoring of neuromuscular blockade during general anaesthesia after reversal with neostigmine

Pirkanmaan hyvinvointialue1 site in 1 country120 target enrollmentSeptember 17, 2024

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Not specified
Sponsor
Pirkanmaan hyvinvointialue
Enrollment
120
Locations
1
Primary Endpoint
To find the incidence of reappearance of nondepolarizing neuromuscular block after reversal with neostigmine
Status
Not yet recruiting
Last Updated
last year

Overview

Brief Summary

To find the incidence of reappearance of nondepolarizing neuromuscularblock after reversal with neostigmine.

Registry
euclinicaltrials.eu
Start Date
September 17, 2024
End Date
TBD
Last Updated
last year
Study Type
Interventional clinical trial of medicinal product

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Maija-Liisa Kalliomäki

Scientific

Pirkanmaan hyvinvointialue

Eligibility Criteria

Inclusion Criteria

  • To find the incidence of reappearance of nondepolarizing neuromuscular block after reversal with neostigmine.
  • Body Mass Index (BMI) <35k9/ mz
  • AGE 18-65 years
  • ASA risk class 1-2

Exclusion Criteria

  • Disease or previous injury of central nervous system
  • Disease or medication affecting peripheral nervous system

Outcomes

Primary Outcomes

To find the incidence of reappearance of nondepolarizing neuromuscular block after reversal with neostigmine

To find the incidence of reappearance of nondepolarizing neuromuscular block after reversal with neostigmine

Study Sites (1)

Loading locations...

Similar Trials